Groowe Groowe / Newsroom / IONS
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

IONS News

Ionis Pharmaceuticals, Inc. Common Stock

FDA Approves High Dose Regimen of SPINRAZA® for Spinal Muscular Atrophy, Reflecting Progress Made Possible Through Decades of MDA Supported Research

globenewswire.com
BIIB IONS

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

globenewswire.com
IONS BIIB

EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)

prnewswire.com
IONS

Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC

businesswire.com
IONS BMY SNY

n-Lorem Publishes Commentary Offering Insight into Potential Commercialization Strategies for Nano-rare Medicines

businesswire.com
IONS

National Triglyceride Alliance Celebrates One Year of Impact and Recognizes National Triglycerides Day

prnewswire.com
IONS ARWR AMRN

Kardigan Announces Multiple Presentations at ACC.26 from its Late-Stage Portfolio of Personalized Cardiovascular Medicines

businesswire.com
IONS SNY BMY

Dallas Drive Leaps to Their First Win of the 2026 Pro Cheer League Season

prnewswire.com
IONS

Form 8-K

sec.gov
IONS

Ionis announces changes to Board of Directors

businesswire.com
IONS